Aim: To examine the role of atorvastatin on volume-overload-induced heart failure and to test the hypothesis that atorvastatin inhibits MMP-2 and 9 expression in heart failure with non-ischemic etiology. Methods: Arteriovenous (AV) fistulatreated rats were administered with atorvastatin (3 mg·kg -1 ·d -1 ) or vehicle for 17 weeks. Ventricular hypertrophy and heart failure were assessed by echocardiography, B-type natriuretic peptide BNP mRNA level and morphological measurement. MMP-2, 9 expression were measured by Western blot and zymography. Results: Atorvastatin decreased left ventricular end diastolic diameter from 6.86±0.51 mm to 6.28±0.37 mm (P<0.05), increased fractioning shortening from 41.4%±4.5% to 52.7%±4.2% (P<0.01), decreased ratio of BNP/GAPDH mRNA level from 0.43±0.03 to 0.27±0.03 (P<0.05). Similar data were observed for morphological measurement. Protein expression and enzyme activity of MMP-2 and 9 in the left ventricle tissue were significantly increased 18 weeks after surgery and atorvastatin also prevented those changes. Conclusion: Left ventricular remodeling induced by AV fistula was profoundly changed by atorvastatin treatment. Hypertrophy was attenuated and global function was improved. These positive effects of atorvastatin on heart failure were associated with decreased MMP-2 and 9 protein expression and enzyme activity.
Introduction
3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, or statins, are widely used clinically as a lipid lowering agent. Many studies have demonstrated that statins prevent the development of heart failure in ischemic heart disease or after myocardial infarction [1] [2] [3] , but those effects of statins are always considered beneficial because of its role on atherosclerotic plaque, such as decreasing plasma cholesterol levels, inhibiting platelet activation, stabilizing plaque, and preventing cell proliferation and migration. However whether statins also inhibit heart failure in non-ischemic heart disease and its mechanism for it is still controversial. Recently, some clinical and basic studies indicated that statins improved cardiac function and survival in non-ischemic heart failure [4] [5] [6] [7] [8] . Concerns have also been raised about the potential adverse effects of statins on heart failure, such as decreased serum cholesterol, which causes the worst outcomes in heart failure [9] and reduced ubiquinone (coenzyme Q-10) [10] [11] [12] , which may adversely affect mitochondrial and cardiac muscle function.
Matrix metalloproteinases (MMP) are a family of zincdependent enzymes that play an important role in the degradation of extracellular matrixes. Changes in expression and activity of several MMP have been identified in failing myocardium, and pharmacological inhibition of some MMP have resulted in the suppression of heart failure [13] [14] [15] [16] [17] . However, MMP species are not uniformly upregulated in heart failure; it is dependent on different heart failure etiologies and different stimulus. For example, MMP-2 and 3 were only upregulated in human non-ischemic dilated cardiomyopathy (DCM); MMP-9 was upregulated while MMP-1 was downregulated in both non-ischemic and ischemic DCM [18] . Some animal strains and heart failure models have been used to demonstrate the mechanisms of statins on heart failure, such as spontaneously hypertensive rats, Dahl saltsensitive rats [19] , the aortic stenosis model, and the rapidpacing-induced model. However, all of the models have their shortcomings and some do not closely mimic the alterations observed clinically in most patients. In the present study, we planned to use the arteriovenous (AV) fistula-induced heart failure model, a well-established and thoroughly characterized model of volume-overload in rats, to evaluate the effect of atorvastatin on heart failure and its role on myocardial MMP-2 and 9 expression and activity.
Materials and methods
Surgical preparation and experimental protocol This study was approved by our institutional animal research committee (Zhejiang University, Hangzhou, China) and conformed to the Guide for the Care and Use of Laboratory Animals published by the United States National Institute of Health (NIH publication, No 85-23, revised 1996). Four-week old, male Sprague-Dawley rats, weighing 70 g, were obtained from the Medical Laboratory Animal Center (Zhejiang University, China). Chronic volume overload was induced using an infrarenal AV fistula model. A ventral abdominal laparotomy was performed to expose a 20.0 mm portion of the aorta and inferior vena cava at a level -3.0 mm below the renal arteries. Both vessels were occluded with finger pressure above and below the fistula site, and an 18 gauge shortbevel needle was passed through the exposed abdominal aorta and advanced into the vena cava. The rats were randomly divided into groups as follows: controls (CON), untreated fistula rats (FIS), treated fistula rats (ATO) and treated with 3 mg·kg -1 ·d -1 a dosage of atorvastatin. The dosage we chose was based on some of our pilot studies and previous published research [20] . The atorvastatin was dissolved in 0.9% saline and administered by daily gavages. The rats were weighed before the initial dosing and weekly thereafter during treatment to ensure constant dosing. Treated fistula rats received the drug beginning 1 week after fistula and until the completion of the study at 18 weeks after surgery.
Echo study The rats were anesthetized with ketamine HCl (50 mg/kg), and transthoracic echocardiography was conducted at 18 weeks. All rats with the HP Sonos 100 (Hewlett-Packard Co, Stockton, CA, USA) with a 10 MHz imaging linear scan probe transducer. The heart was imaged at the level of the papillary muscles to obtain left ventricle (LV) wall thickness and fractional shortening. Three beats were averaged for each measurement.
We determined the LV end diastolic diameter (LVEDd) as the widest and the end systolic diameter (LVEDs) as the narrowest dimension in the M-mode recordings. LV fractioning shortening (FS) was calculated according to the following formula: LV FS (%)=(LVEDd-LVEDs)/LVEDd×100 Zymography of MMP activity LV myocardial samples were homogenized in 2 mL of an ice-cold extraction buffer containing cacodylic acid (10 mmol/L), NaCl (0.15 mol/L), ZnCl (20 mmol/L), NaN 3 (1.5 mmol/L), and 0.01% Triton X-100 (pH 5.0). The homogenate was then centrifuged (4 °C, 10 min, 12 000×g) and the supernatant was saved and stored at -80 °C.
The myocardial extracts were loaded onto SDS-PAGE gel containing 1 mg/mL gelatin. The gelatin was stirred and heated at 50 °C for 1 h before adding to the gel. The myocardial extracts, at a final protein content of 4 µg, were loaded onto the gels using a 3:1 sample buffer (10% SDS, 4% sucrose, 0.25 mol/L Tris-HCl, and 0.1% bromophenol blue, pH 6.8).
The gels were run at 20 mA/gel, maintaining a running buffer temperature of 4 °C. After that, the gels were washed twice with 2.5% Triton X-100 for 30 min each on ice and incubated with substrate buffer (50 mmol/L Tris-Cl, 5 mmol/L CaCl 2 , 0.02% NaN 3 , and 1% Triton X-100, pH 8) at 37 °C for 18 h. After incubation, the gels were stained with 0.05% Brilliant Blue R-250 (Sigma, St Louis, MO, USA), destained with 10% acetic acid and 20% methanol (v/v), and digitized. The gelatinolytic activity was tested as specific MMP activity by adding EDTA and phenylmethylsulphonyl fluoride PMSF. EDTA inhibited gelatinolytic activity, but PMSF did not.
Immunoblot analysis Proteins were isolated from the LV tissue, and 50 µg of total proteins were analyzed on 10% SDS-PAGE under the reducing condition. The proteins were blotted onto Polyvinylidene fluoride PVDF membranes and incubated in 5% non-fat milk in PBS for at least 1 h. After incubation, the PVDF membranes were subjected to immunoblot analysis with rabbit polyclonal antibodies to MMP-2 or MMP-9 (1:200 dilutions; Santa Cruz Biotechnology, Santa Cruz, CA, USA) or actin (1:400 dilutions, Santa Cruz Biotechnology, USA) Immune complexes were detected with appropriate horseradish peroxidase-conjugated secondary antibodies and quantitated with Quantity One Image software (Bio-Rad, Hercules, CA, USA).
RNA isolation and RT-PCR analysis Total RNA was extracted from the LV tissue using TRIzol reagent. Briefly, total RNA (2 µg) was converted to single stranded cDNA using a reverse transcription system (Promega, Madison, WI, USA). The target cDNA was amplified using the following sense primer and antisense primers for rat brain natriuretic peptide (BNP). Sense: 5'-GGA AAT GGC TCA GAG ACA GCT C-3'; antisense: 5'-AAG TCT CTC CTG GAT CCG GAA G-3'. For GAPDH, sense: 5'-AAG GTC GGA GTC AAC GGA TTT-3'; and antisense: 5'-AGA TGA TGA CCC TTT TGG CTC-3'. The amplification cycles were 95 °C for 1 min, 55 °C for 1 min, and 72 °C for 1 min. After 30 cycles, the PCR products were separated by electrophoresis on 1.8% agarose (106 bp for BNP and 352 bp for GADPH).
Morphological measurement The LV was fixed with 4% paraformaldehyde, embedded in paraffin, sectioned at a thickness of 6 µm, and stained with hematoxylin-eosin and van Gieson staining. The degree of collagen fiber accumulation was quantified blindly on 6 sections per animal (12 randomly selected fields per section), and the ratio of the van Gieson staining fibrosis area to the total myocardium area was calculated.
Statistical analysis Statistical analyses were performed with SPSS 10.0 software (SPSS Inc, Chicago, IL, USA). All grouped data were expressed as mean±SD. Grouped data comparisons were made by one-way ANOVA followed by Bonferroni post-hoc testing. A P value of <0.05 was considered statistically significant.
Results

Left ventricular dilation and hypertrophy
The FIS rats developed remarkable left ventricular dilation and hypertrophy compared with the CON rats at 18 weeks. LVEDd, LVEDs, and heart weight HW/body weight (BW) increased significantly in the FIS rats compared with the CON rats. FS in the FIS rats (41.4%±4.5%) decreased significantly compared with the CON rats (55.1%±4.5%, P<0.01). Atorvastatin treatment suppressed left ventricular dilation and hypertrophy significantly. LVEDd, LVEDs, and HW/BW in the ATO rats decreased remarkably compared with the FIS rats. Atorvastatin treatment also improved FS from 41.4%±4.5% to 52.7%±4.2% (P<0.01; Table 1 ).
Marked left ventricular dilation and interstitial fibrosis were observed in the FIS group compared with the CON group. Atorvastatin treatment inhibited the left ventricular dilation and interstitial fibrosis significantly (Figures 1, 2) . Atorvastatin reduced the ratio of fibrosis from 8.6%±1.4% in the FIS group to 6.4%±1.2% in the ATO group (P<0.05; Figure 2B ).
Left ventricular BNP mRNA level The mRNA levels of BNP increased about 2-fold in the FIS group compared with the CON group. Atorvastatin treatment reduced the mRNA levels of BNP significantly, and the ratio of BNP/GAPDH in the FIS group decreased from 0.43±0.03 to 0.27±0.03 in the ATO group (P<0.05, Figure 3A, 3B) . level at 18 weeks after surgery was significant higher compared with the CON rats. Although the protein level of MMP-9 in the ATO rats was still significantly higher than the CON group, treatment with atorvastatin 17 week after surgery markedly inhibited the MMP-9 protein expression compared with the FIS rats (P<0.01, Figure 4A , 4B). Atorvastatin treatment slightly, but still significantly, decreased the protein level of MMP-2 in the ATO rats compared with the FIS rats (P<0.05; Figure 4A , 4B). There were no significantly differences in the MMP-2 protein level between the ATO rats and the CON rats. Changes of MMP-9 and MMP-2 activity measured by zymography were consistent with the changes of MMP-9 and MMP-2 protein levels ( Figure 5 ).
Effect of atorvastatin on myocardial MMP-9 and MMP-2 protein level and activity In the FIS rats, the MMP-9 protein
Discussion
The rats with an AV fistula can develop heart failure with normal sodium balance. This heart failure experimental model is characterized by the hemodynamic and neurohormonal changes, which closely mimic the alterations observed clinically in patients with heart failure [21, 22] . Previous reports indicated that cardiac hypertrophy occurred within 1 week after AV fistula operation, while decompensate heart failure developed 8-16 weeks after the creation of AV fistula, characterized by circulatory congestion and decreased cardiac function [23] . The present study demonstrates that long-term administration of atorvastatin could prevent volume-overload-induced heart failure and left ventricular hypertrophy. More and more research has indicated that statins have therapeutic properties that are of potential benefit to heart failure with non-ischemic etiologies, irrespective of lipid levels. Rainer et al [24] demonstrated that simvastatin normalized autonomic neural control and reduced plasma norepinephrine in rapid-pacing-induced heart failure rabbits. Chen et al [20] demonstrated that simvastatin, initiated after hypertrophy, inhibited oxidative stress and prevented heart failure in rats with aortic stenosis. Inflammatory cytokines may also be involved in the role of statins on heart failure. Inflammatory cytokines, which are produced by activated macrophages, vascular wall cells, and cardiac myocytes, were elevated in heart failure. These cytokines, especially TNF-α and interleukin-6 (IL-6), exert negative inotropic effects and induce apoptosis in cardiac myocytes. Short-term simvastatin therapy has been tested to improve cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy by reducing plasma concentrations of TNF-α and IL-6 [4] . Failing myocardium of patients with DCM was characterized by upregulation of NADPH oxidase-mediated ROS release associated with increased Rac1 activity. Oral atorvastatin or pravastatin treatment could inhibit myocardial Rac1-GTPase activity [5] . These data suggest that antioxidative effects of statins may also be beneficial for heart failure. Other mechanisms of statins, such as promoting angiogenesis [25] , increasing endothelial NO production, improving endothelial function and endothelial progenitor cell mobilization [3] , have been demonstrated to take effect in heart failure after myocardial infarction, but whether these effects are also beneficial to heart failure with non-ischemia etiologies is still unknown.
Interstitial collagenases (such as MMP-1 and MMP-13), stromelysins (such as MMP-3), and gelatinases (such as MMP-2 and MMP-9) are expressed in mammalian myocardium. The relationship between MMP and the LV remodeling process has been demonstrated through the use of animal models of developing chronic heart failure, transgenic models, and the use of pharmacological MMP inhibition studies. Clinical research has also shown that MMP are involved in the process of LV remodeling and heart failure. The Framingham Heart Study demonstrated that plasma MMP-9 levels were associated with increased LV diastolic dimensions and increased wall thickness in men [26] . Levels of plasma MMP-2 were tested for an association with neurohormonal activation and levels of noradrenaline in human heart failure [27] . In ischemic heart failure, MMP-2 and MMP-13 levels increased, and statins were demonstrated to ameliorate ventricular remolding through inhibiting them [28] . Fibrosis during the progression of heart failure was also associated with increased MMP [29] . However, the types of MMP expressed in normal and congestive heart failure states remains unclear. The molecular basis for a selective portfolio of MMP to be increased within the failing human myocardium is likely due to the type, degree, and duration of the specific extracellular stimuli that are presented. Statins have been claimed to inhibit MMP in atherosclerosis [30] [31] [32] , but its role on MMP in non-ischemic heart failure is not clear. This study found that atorvastatin prevented heart failure and LV hypertrophy, and these effects were associated with decreased MMP-2 and MMP-9 protein expression and activity. Several possible mechanisms may be involved in the role of statins on the MMP system. Decreasing the secretion of inflammatory factor by statins is one of the possible mechanisms. For example, TNF-α, an important MMP regulator which activates MMP through the MAPK, NF-kappaB, and AP-1 pathways [33] [34] [35] , may be involved in the role of statins on MMP. Turner NA et al [36] also demonstrated that simvastatin reduces MMP-9 secretion from human saphenous vein, smooth muscle cells by inhibiting isoprenoid formation and RhoA kinase. But whether it is the same in myocardium is unknown. More research needs to be done about the role of statins on different MMP species in heart failure. In summery, our study demonstrated that atorvastatin may be beneficial for non-ischemic heart failure and may inhibit MMP-2 and 9 expression and activity.
